PRO-spectus’ Post

In clinical development, capital efficiency and high quality can co-exist. Danforth's Rene Stephens, MSHS shares insights on macro factors affecting clinical resourcing and program execution, and how to manage costs while upholding performance. https://lnkd.in/eFUAHseK #clinicaldevelopment #clinicaloperations

🌟 Exploring the Complexities of STGs and Pharmacy & Therapeutics Committees 🌟 As professionals deeply engaged in healthcare, we understand that the pursuit of optimal patient care is a multifaceted journey. Today, I want to shine a light on the intricate realm of Standard Treatment Guidelines (STGs) and Pharmacy & Therapeutics (P&T) Committees – two pillars crucial to navigating the landscape of modern healthcare. STGs serve as blueprints, offering standardized protocols and procedures to guide healthcare providers in delivering evidence-based care. They streamline decision-making processes, ensuring consistency and quality across various healthcare settings. However, in their implementation, they often encounter a myriad of challenges. One such challenge lies in the dynamic nature of medical science. With advancements and discoveries occurring at a rapid pace, STGs must continually evolve to incorporate the latest evidence and best practices. Balancing the need for agility with the imperative of maintaining robust standards poses a perpetual challenge for healthcare systems worldwide. Moreover, the diversity of patient populations further complicates the formulation and application of STGs. What works effectively for one demographic or region may not necessarily yield the same outcomes elsewhere. Cultural, socioeconomic, and genetic factors all play pivotal roles, necessitating nuanced adaptations of treatment guidelines to ensure equitable and personalized care for all. Enter the Pharmacy & Therapeutics Committees – the guardians of medication management and therapeutic efficacy within healthcare institutions. Charged with the critical task of evaluating pharmaceutical products and formularies, these committees wield immense influence over patient outcomes. Yet, their deliberations often navigate through a labyrinth of considerations. From assessing drug efficacy and safety profiles to balancing cost-effectiveness and accessibility, P&T Committees face a delicate balancing act. The decisions they make ripple through the entire healthcare ecosystem, impacting treatment pathways, resource allocation, and ultimately, patient well-being. However, amidst these complexities lie boundless opportunities for collaboration, innovation, and advancement. By fostering interdisciplinary dialogue and leveraging technology and data-driven insights, we can navigate the intricacies of STGs and P&T Committees with greater efficacy and precision. As stakeholders committed to advancing healthcare excellence, let us embrace these challenges as catalysts for growth and transformation. Together, let us forge a future where STGs and P&T Committees serve as beacons of excellence, guiding us towards a world of healthier, happier communities. #Healthcare #STGs #PTCommittees #EvidenceBasedMedicine #PatientCare #Collaboration #Innovation

Our latest blog is out on how to use evidence to drive stakeholder engagement. This is part 1 of 5 and it dives into the importance of an Integrated Evidence Plan (IEP) and how Medical Affairs are needed at the table to translate unmet informational needs from doctors and physicians into study designs and ultimately data that then goes back out to the field to change hearts and minds -- and improve care. It all starts with the strategy and how to build that business case for an IEP so that the full value of a therapy can be realized. #evidence #medicalaffairs #strategy #IQVIA https://lnkd.in/eCHj2eRb

We’re proud to be a member of MEDITECH’s Alliance Network as an Alliance Innovator and are looking forward to attending MEDITECH LIVE 24 where MEDITECH users will discover how they can sharpen their focus and make transformational change together to improve healthcare. As a leading provider of drug knowledge that helps healthcare professionals make precise medication decisions, we’re excited to join this conversation!   💡 FDB MedKnowledge® is the healthcare industry’s most widely used source of drug information for providers at the point of care. FDB supplies drug formulary data, order string, and clinical screening content, which is integrated into all MEDITECH platforms across the United States and Canada. FDB supports functions of inpatient dispensing, medication reconciliation, and prescription writing and is used for medication decision support across the inpatient, emergency department, discharge, and ambulatory care settings.   💡 FDB Pharmacogenomic CDS has also been integrated into MEDITECH Expanse Genomics to help advance precision medicine by bringing the power of pharmacogenomic decision support to more clinicians, including those at rural and community hospitals. Access to this valuable, patient-specific medication data will help inform better decisions and enhance the safety and effectiveness of patient care.   Schedule a meeting with the FDB Team during #MEDITECHLIVE2024 to learn more about our latest innovations: https://bit.ly/3TDCYAz | #DrugKnowledge #MedicationDecisionSupport #MoveBeyondTheFrame #Innovation #Pharmacogenomics

🌟 I’m often surprised at how many biopharma companies have websites that lack a strong patient-facing presence. Here’s why this is a missed opportunity: • Education: Equip patients, caregivers, and healthcare professionals with valuable information about conditions, treatments, and trials. 📚 • Trust: Build credibility and demonstrate transparency in your clinical trial processes. 🤝 • Awareness: Support patient advocacy and create a sense of community. 🌎 • Branding: Highlight your medications, clinical trials, and patient support programs. 🏥 • Engagement: Foster ongoing relationships with patients and gather valuable feedback. 🗣️ At Citeline, we’re all about helping biopharma companies connect with patients and healthcare providers in a way that’s simple and effective. Our goal is to make it easier for companies to get patients interested in clinical trials while reducing the burden on sites and patients. We design websites that fit the unique needs of clinical trial sponsors, focusing on a patient-first approach and creating meaningful connections with patient communities. If you want a more engaging and friendly patient-facing website, let’s chat! 💬 #citeline #clinicaltrial #clinicaltrialpatients #biopharma #patientrecruitment

Our focus at SES is on measurable education that accelerates clinical practice and optimizes patient outcomes. Discover the impact of our hubs on HCP learning at: https://loom.ly/OlGnPTw #PatientCare #ProfessionalDevelopment

🌟 Excited for #MeditechLIVE! 🌟 I am particularly looking forward to this session. With a strong background and passion for pharmacy, I recognize the critical importance of pharmacy informatics in advancing patient care. Often overlooked, the role of pharmacy is integral in shaping patient outcomes, and leveraging informatics can further enhance our impact within the health system. Healthcare IT is rapidly evolving, and I'm looking forward to diving deeper into the continuing education sessions on how we can harness the power of data to improve patient outcomes. 🏥💡 Let’s connect and collaborate on leveraging these technologies to shape the future of healthcare! #HealthIT #DataAnalytics #Interoperability #DataMining #PharmacyInformatics #ClinicalInformatics #DecisionSupport

My new article "preprint" outlines essential competencies, envisions emerging perspectives for pharmacy practice, and recognizes pharmacointelligence as a dynamic force reshaping the field, fostering efficiency, personalization, and efficacy in the era of data-driven healthcare. https://lnkd.in/gGy32zT9

The role of the Chief Pharmacy Officer in today’s healthcare ecosystem is crucial. Interesting read on the key priorities Chief Pharmacy Officers are navigating such as ambulatory growth, 340B optimization, and automation/process standardization.

How do you measure implementation of patient-centric activities in a clinical trial? We share one way that we tried to gauge this, among an audience of industry, academia, healthcare organisations, and trial service providers who attended the Global Clinical Trials Connect 2024 conference. After reviewing what innovation in clinical trials means to patients, and outlining the 14 components of the 'Personalized Clinical Trials Framework' from #TransCelerate, we asked the audience which of these activities they have implemented in a clinical trial. Out of 46 respondents in the audience: 👩🎓 The highest activity implemented was providing patients education about the clinical trial (32). 💡📱The second highest activities implemented were creating general awareness about clinical trials, and enabling collection of digital data from patients during the trial (23). 🙏 Fewer had involved patients in providing input into the trial design or protocol (15). 🧓 The lowest activities were those providing patients with convenience - decentralised participation via direct delivery of therapies or alternative procedure locations, and flexibility in scheduling (7-9). There seems to be more work needed to 'walk the talk' in practice, when it comes to patient centricity in clinical trials. If trial sponsors also conducted a similar measure of their patient-centric activity implementation, we wonder what this would look like for different organisations? We welcome your thoughts and feedback! www.patient-co-next.com #patientengagement #patientcentricity #patientadvocacy #clinicaltrials #research #drugdevelopment #patientinsights #patientrecruitment #clinicaloperations #pfmd #pfdd #patientjourney #decentralizedclinicaltrials #directtopatients #personalizedclinicaltrials #patientretention #innovation #clinicaldevelopment #corvusglobalevents #measurement #implementation